HK1223098A1 - 雜芳基取代的吡唑 - Google Patents

雜芳基取代的吡唑

Info

Publication number
HK1223098A1
HK1223098A1 HK16111252.2A HK16111252A HK1223098A1 HK 1223098 A1 HK1223098 A1 HK 1223098A1 HK 16111252 A HK16111252 A HK 16111252A HK 1223098 A1 HK1223098 A1 HK 1223098A1
Authority
HK
Hong Kong
Prior art keywords
heteroaryl substituted
substituted pyrazoles
pyrazoles
heteroaryl
substituted
Prior art date
Application number
HK16111252.2A
Other languages
English (en)
Inventor
Anne Mengel
Marion Hitchcock
Anja Richter
Lars Brfacker
Hans Briem
Gerhard Siemeister
Wilhelm Bone
Amaury Ernesto Fernndez-Montalvn
Jens Schrder
Simon Holton
Cornelia Preusse
Ursula Mnning
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1223098A1 publication Critical patent/HK1223098A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111252.2A 2013-06-21 2016-09-26 雜芳基取代的吡唑 HK1223098A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13173298 2013-06-21
PCT/EP2014/062689 WO2014202584A1 (en) 2013-06-21 2014-06-17 Heteroaryl substituted pyrazoles

Publications (1)

Publication Number Publication Date
HK1223098A1 true HK1223098A1 (zh) 2017-07-21

Family

ID=48651939

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111252.2A HK1223098A1 (zh) 2013-06-21 2016-09-26 雜芳基取代的吡唑

Country Status (8)

Country Link
US (1) US9745285B2 (zh)
EP (1) EP3010901B1 (zh)
JP (1) JP2016525075A (zh)
CN (1) CN105452237A (zh)
CA (1) CA2916194A1 (zh)
ES (1) ES2652305T3 (zh)
HK (1) HK1223098A1 (zh)
WO (1) WO2014202584A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
CN105164116A (zh) * 2013-03-21 2015-12-16 拜耳制药股份公司 杂芳基取代的吲唑
CA2916116A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US20160168130A1 (en) * 2013-06-21 2016-06-16 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
JP6545199B2 (ja) 2014-06-17 2019-07-17 バイエル ファーマ アクチエンゲゼルシャフト 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類
CU20170029A7 (es) 2014-09-19 2017-08-08 Bayer Pharma AG Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
BR112017016193B1 (pt) 2015-01-28 2023-02-23 Bayer Pharma Aktiengesellschaft Derivados de 4h-pirrolo[3,2-c]piridin-4-ona
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
AU2021347288A1 (en) 2020-09-23 2023-05-04 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
CA3198202A1 (en) 2020-10-09 2022-04-14 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863282B2 (en) * 2003-03-14 2011-01-04 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ718622A (en) 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN107021951B (zh) * 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
ES2620316T3 (es) 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
CN105164116A (zh) 2013-03-21 2015-12-16 拜耳制药股份公司 杂芳基取代的吲唑
EP2976334A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
WO2014147203A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
WO2014202583A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US20160168130A1 (en) 2013-06-21 2016-06-16 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2916116A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CA2916103A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
CA2961586A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CA2961578A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CU20170029A7 (es) 2014-09-19 2017-08-08 Bayer Pharma AG Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios
CN107148420A (zh) 2014-09-19 2017-09-08 拜耳制药股份公司 苄基取代的吲唑类化合物

Also Published As

Publication number Publication date
CA2916194A1 (en) 2014-12-24
JP2016525075A (ja) 2016-08-22
US9745285B2 (en) 2017-08-29
CN105452237A (zh) 2016-03-30
US20160145238A1 (en) 2016-05-26
ES2652305T3 (es) 2018-02-01
WO2014202584A1 (en) 2014-12-24
EP3010901B1 (en) 2017-09-13
EP3010901A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
HK1223097A1 (zh) 雜芳基取代的吡唑
HK1223098A1 (zh) 雜芳基取代的吡唑
HK1223350A1 (zh) 雜芳基取代的吲唑
ZA201505397B (en) Novel pyrazole derivative
HK1222846A1 (zh) 取代的苄基吡唑
HK1221717A1 (zh) 取代的苄基吡唑
HK1212345A1 (zh) -取代的吡咯並二氮雜卓和吡唑並二氮雜卓
HRP20170919T1 (hr) Novi derivati pirazola
HK1222852A1 (zh) 二氨基雜芳基取代的吡唑
HK1217324A1 (zh) 二氨基雜芳基取代的吲唑
HRP20171890T1 (hr) Supstituirani imidazopiridazini
HK1222173A1 (zh) 取代的吡唑並嘧啶基氨基-吲唑類
HK1223362A1 (zh) 取代的吡唑並吡啶胺
HK1220972A1 (zh) 取代的噻唑並嘧啶
IL246271A0 (en) Converted piperidinyl-tetrahydroquinolines
HRP20180644T1 (hr) Derivat pirazola